NASD · Healthcare · Biotechnology · USA
SAB Biotherapeutics Inc is a micro cap company (market value under $300 million) in the Biotechnology industry.
SAB Biotherapeutics is a clinical-stage biopharmaceutical company developing multi-specific human immunoglobulin G antibodies to treat and prevent immune and autoimmune disorders. The company's lead candidate, SAB-142, targets diabetes using a disease-modifying approach. SAB Biotherapeutics utilizes proprietary technology based on transchromosomic cattle to produce therapeutic antibodies without requiring human plasma donors.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the SAB Biotherapeutics Inc stock.
Not valued: We cannot value this company yet.
10 more funds hold it; the full list is part of the paid plan.
129 more in this industry show a wider margin of safety.
We do not publish a verdict on SABS yet. We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.
We do not publish one (as of the 2026-11-17 close). We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.